Method of Using GPR35 to Identify Metabolic-Stabilizing Compounds

Abstract

The present invention relates to a method for identifying a metabolic stabilizing compound, comprising: a) contacting a candidate compound with GPR35, and b) determining whether GPR35 functionality is increased, wherein an increase in GPR35 functionality is indicative of the candidate compound being a metabolic stabilizing compound. The invention further relates to a method for treating or preventing a metabolic-related disorder, comprising administering to an individual in need thereof an effective amount of a GPR35 modulator.

1 . A method for identifying a metabolic-stabilizing compound, comprising:
 a) contacting a candidate compound with GPR35, and   b) determining whether GPR35 functionality is increased,   wherein an increase in GPR35 functionality is indicative of the candidate compound being a metabolic-stabilizing compound.   
     
     
         2 . The method of  claim 1 , wherein said GPR35 is human. 
     
     
         3 . The method of  claim 1 , wherein said determining comprises a second messenger assay. 
     
     
         4 . A metabolic stabilizing compound identified according to the method of  claim 1 . 
     
     
         5 . The compound of  claim 4 , wherein said metabolic stabilizing compound is a GPR35 agonist. 
     
     
         6 - 8 . (canceled) 
     
     
         9 . A method for treating or preventing a metabolic-related disorder in an individual in need thereof, comprising administering to said individual an effective amount of the compound of  claim 4 . 
     
     
         10 . The method of  claim 9 , wherein said metabolic-related disorder is diabetes, Type I diabetes, Type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, obesity, aging, Syndrome X, atherosclerosis, heart disease, stroke, hypertension, or peripheral vascular disease. 
     
     
         11 . The method of  claim 9 , wherein said metabolic-related disorder is Type II diabetes. 
     
     
         12 . The method of  claim 9 , wherein said metabolic-related disorder is dyslipidemia. 
     
     
         13 . The method of  claim 9 , wherein said method further comprises administering to said individual an effective amount of an agent used for the treatment of diabetes, blood lipid disorders, or obesity. 
     
     
         14 . The method of  claim 9 , wherein the individual is a mammal. 
     
     
         15 . The method of  claim 9 , wherein the individual is a human. 
     
     
         16 - 19 . (canceled) 
     
     
         20 . A method for treating or preventing a metabolic-related disorder, comprising administering to an individual in need thereof an effective amount of a GPR35 modulator. 
     
     
         21 . The method of  claim 20 , wherein said modulator is an agonist. 
     
     
         22 . The method of  claim 20 , wherein said metabolic-related disorder is diabetes, Type I diabetes, Type II diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, obesity, aging, Syndrome X, atherosclerosis, heart disease, stroke, hypertension, or peripheral vascular disease. 
     
     
         23 . The method of  claim 20 , wherein said metabolic-related disorder is Type II diabetes. 
     
     
         24 . The method of  claim 20 , wherein said metabolic-related disorder is dyslipidemia. 
     
     
         25 . The method of  claim 20 , wherein said method further comprises administering to said individual an effective amount of an agent used for the treatment of diabetes, blood lipid disorders, or obesity. 
     
     
         26 . The method of  claim 20 , wherein the individual is a mammal. 
     
     
         27 . The method of  claim 20 , wherein the individual is a human. 
     
     
         28 - 35 . (canceled)